As you may already be aware, one of the primary reasons the National Cancer Institute is building the new Riverside Research Park is to provide space for “synergistic partners” from academia and Industry to work together to cure cancer.  I was just alerted to several new opportunities by my friends at FITCI

A new collaboration opportunity, “Gene Expression Signature Predictive of Response to Chemotherapy” has been added to the NCI Technology Transfer Center web site. Please go to: http://ttc.nci.nih.gov/opportunities/opportunity.php?opp_id=1881

A new collaboration opportunity, “Antibody and Immunotoxin Treatments for Mesothelin-Expressing Cancers” has been added to the NCI Technology Transfer Center web site. Please go to: http://ttc.nci.nih.gov/opportunities/opportunity.php?opp_id=1883

A new collaboration opportunity, “Knockdown and Enhanced Expression of P53 Isoforms to Treat Age-Related Disorders and Cancer” has been added to the NCI Technology Transfer Center web site. Please go to: http://ttc.nci.nih.gov/opportunities/opportunity.php?opp_id=1885

A new collaboration opportunity, “Engineered Biological Pacemakers” has been added to the NCI Technology Transfer Center web site. Please go to: http://ttc.nci.nih.gov/opportunities/opportunity.php?opp_id=1884

A new collaboration opportunity, “Novel Kinase Inhibitors Targeting the PH Domain of AKT for Preventing and Treating Cancer” has been added to the NCI Technology Transfer Center web site. Please go to: http://ttc.nci.nih.gov/opportunities/opportunity.php?opp_id=1882

via fredcobio.wordpress.com

Interested? Or know someone who might be?

Click on the links to see more details. Spread the word!

(HT Jim Hardy @fredcobio)

Posted via web from sally church’s posterous